Answer to the Letter to the Editor of Zambre, et al. concerning “A new hernia blocking system prevents lumbar disc herniation recurrence and disc degeneration: 2 years results of a multicentric clinical investigation” Authors: Ignasi Català, Oscar Godino, all the study authors Published: 2026 To the Editor: We thank the authors of the Letter to the Editor (Zambre et al., 2026) for their interest in our work (Català et al., 2025) and for their comments, which provide an opportunity to clarify important aspects of our study design and interpretation. First, regarding the absence of a concurrent control group, we agree that randomized controlled trials represent the gold standard to establish comparative effectiveness. However, our study was explicitly designed as a first-in-human, prospective, multicentric clinical investigation with a primary focus on safety and performance in a strictly defined high-risk population, as is specifically recognized and discussed in the discussion section of the manuscript. In this context, the use of external benchmarks, such as previously published cohorts with comparable inclusion criteria, is an accepted and pragmatic approach in early-phase device evaluation. Importantly, our manuscript does not claim causal superiority but reports observed outcomes in a well-characterized cohort, which are clearly contextualized against existing literature. The suggestion that our conclusions overstate the effectiveness of the device does not fully reflect the cautious interpretation provided. The absence of symptomatic recurrent lumbar disc herniation (rLDH) at 24 months, together with narrow confidence intervals, represents a clinically meaningful observation in a population historically associated with high recurrence rates. While further confirmatory studies are guaranteed, these findings should not be dismissed as merely anecdotal, particularly given the consistency across clinical, radiological, and patient-reported outcomes. Regarding the lack of formal statistical comparison with external cohorts, we deliberately avoided inappropriate inferential analyses across datasets. Instead, we reported descriptive outcomes and confidence intervals, which is methodologically sound and aligned with the exploratory nature of the study. The comments on comparisons with other annular closure devices, such as Barricaid, are noted. However, the objective of our study was not to establish comparative performance but to report the first clinical experience with a novel device. In addition, such comparisons should be interpreted with caution, as annular closure devices are not currently considered standard of care, and their availability remains limited in several markets, including Europe. Consequently, direct comparative analyses were beyond the scope of this investigation. Nevertheless, our results fall within, and in some aspects compare favorably to, the range of outcomes reported for existing mechanical annular closure systems, supporting the biological plausibility and clinical relevance of the approach. Several safety concerns raised by the authors, including infection risk, fibrosis-related complications, anchor loss, or issues in the setting of dural tears, are largely hypothetical and not supported by the clinical data obtained in this study. Over a 24-month follow-up, no device- or procedure-related serious adverse events were observed, and no cases of anchor loses, clinically relevant fibrosis, or infection were reported. While vigilance is always warranted with implantable technologies, it is important to distinguish between theoretical risks and observed clinical outcomes. Our findings provide empirical evidence supporting a favorable safety profile in the studied population. Regarding the concern about the performance of the device in higher-risk patient subgroups, it is important to emphasize that the eligibility criteria of the study were deliberately defined in alignment with the implant instructions for use. As such, the study population is representative of the patients for whom the device is intended. Consequently, the outcomes reported reflect the performance of the device within its intended-use population, rather than in broader or non-indicated clinical scenarios. Evaluation in off-label populations would require specifically designed studies and should not be inferred from the present data. Finally, considerations regarding cost-effectiveness and real-world adoption, while relevant, fall outside the scope of the present study. These aspects require dedicated health economic analyses and larger comparative datasets, that will be performed in the next steps of the clinical development of the device. In conclusion, we believe that our study provides robust firstin-human clinical evidence supporting the safety and performance of this novel hernia blocking system in patients at high-risk for hernia recurrence. While further comparative studies are warranted, the current data represent a meaningful contribution to the field and should be interpreted within the appropriate context of early clinical investigation. Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Oscar Godino reports financial support, administrative support, article publishing charges, equipment, drugs, or supplies, and statistical analysis were provided by Neos Surgery SL. Oscar Godino reports a relationship with Neos Surgery SL that includes: consulting or advisory. Ignaci Catala reports a relationship with Neos Surgery SL that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.